Newron Provides Update on FDA Clinical Hold and Phase 3 ENIGMA-TRS Development Program
FROM THE WIRE · FINANCE.YAHOO.COM
Management call today at 3.30 pm CEST Newron received the anticipated FDA written communication on clinical hold at U.S. study centers and is reviewing feedback and preparing its response ENIGMA-TRS 1 enrollment expected to be completed by mid-October; topline 12-week data…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bearishFDA clinical hold on a key study is material negative news for the biotech stock price.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Newron received FDA written communication of clinical hold at U.S. study centers.
- 02ENIGMA-TRS 1 enrollment expected complete by mid-October with 12-week data in Q1 2027.
- 03ENIGMA-TRS 2 enrollment continuing outside the U.S. with additional clinical sites being added.
- 04The company is reviewing FDA feedback and preparing its response.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets